January 10, 2011
$4M For Alzheimer's Testing Co.
Neuroptix Corp., an Acton company working on a test for the detection of Alzheimer's disease, has received $4 million in venture funding.
The $4 million is the first tranche of a Series C funding round. The investment, led by Inventages, will be funded in two tranches totaling $8 million, according to Neuroptix.
The Neuroptix SAPPHIRE II System is a non-invasive eye test for Alzheimer's. It works by looking for proteins that form in both the brain and the lens of the eye in people with the disease.
WBJ Web Partners
Most Recent
Most Recent
0 Comments